Sinovac Biotech (SVA) shareholder, Heng Ren Silk Road Investments, sent an open resolution to Sinovac’s shareholders outlining the decisive action that Sinovac’s Board of Directors must take to pay shareholders the $55 cash dividend before the July 8 board vote, which would remove uncertainty, restore credibility and improve investor confidence in Sinovac.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVA:
- Prime Success responds to Sinovac Biotech in letter to fellow shareholders
- Vivo Capital issues letter to Sinovac Biotech shareholders
- Sinovac Faces Nasdaq Compliance Deadline Amid Auditor Transition
- Sinovac Biotech receives noncompliance notification from Nasdaq
- Sinovac Biotech Calls Special Shareholder Meeting Amid Board Reshuffle